KNSA Kiniksa Pharmaceuticals Ltd

$38.29

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 10/6/2025

About Kiniksa Pharmaceuticals Ltd

No Company Description Available

Website: N/A

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1730430
Address
CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON, BM
Valuation
Market Cap
$1.47B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
3.35
Performance
EPS
$-0.60
Dividend Yield
—
Profit Margin
-10.20%
ROE
-9.85%
Technicals
50D MA
$21.04
200D MA
$22.51
52W High
$28.15
52W Low
$16.87
Fundamentals
Shares Outstanding
42M
Target Price
$35.57
Beta
0.31

KNSA EPS Estimates vs Actual

● Estimated
● Actual

KNSA News & Sentiment

Oct 06, 2025 • Zacks Commentary SOMEWHAT-BULLISH
GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal
Genmab stock surges 21.9% after striking an $8 billion deal to buy Merus, adding a late-stage cancer treatment candidate to its proprietary oncology pipeline.
Oct 06, 2025 • Zacks Commentary BULLISH
Here's What Could Help Kiniksa Pharmaceuticals International, plc ( KNSA ) Maintain Its Recent Price Strength
If you are looking for stocks that are well positioned to maintain their recent uptrend, Kiniksa Pharmaceuticals International, plc (KNSA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Sep 29, 2025 • Zacks Commentary NEUTRAL
Beat the Market the Zacks Way: Helios Technologies, InterDigital, UnitedHealth in Focus
Helios Technologies, InterDigital and UnitedHealth shine as Zacks' strategies deliver strong gains across model portfolios.
Sep 26, 2025 • Zacks Commentary NEUTRAL
CDTX Stock Soars 218% YTD on Positive Updates From Influenza Program
Cidara Therapeutics' shares surge 218% this year after its flu candidate CD388 hits key mid-stage study goals and advances into pivotal testing.
Sep 25, 2025 • Zacks Commentary NEUTRAL
QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study
uniQure N.V. shares surge nearly 248% after its gene therapy candidate, AMT-130, met key goals in a pivotal Huntington's disease study.
Sep 25, 2025 • Zacks Commentary SOMEWHAT-BULLISH
ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure
Acadia Pharmaceuticals stock tumbles 10% after its phase III hyperphagia study failure, but growth remains driven by Nuplazid, Daybue and a robust pipeline.
Sentiment Snapshot

Average Sentiment Score:

0.184
50 articles with scored sentiment

Overall Sentiment:

Bullish

KNSA Reported Earnings

Feb 25, 2025
Dec 31, 2024 (Pre market)
-0.25 Surprise
  • Reported EPS: $-0.12
  • Estimate: $0.13
  • Whisper: —
  • Surprise %: -192.3%
Oct 29, 2024
Sep 30, 2024 (Pre market)
-0.25 Surprise
  • Reported EPS: $-0.18
  • Estimate: $0.07
  • Whisper: —
  • Surprise %: -366.7%
Jul 23, 2024
Jun 30, 2024 (Pre market)
0.01 Surprise
  • Reported EPS: $-0.06
  • Estimate: $-0.07
  • Whisper: —
  • Surprise %: 14.3%
Apr 23, 2024
Mar 31, 2024 (Pre market)
-0.09 Surprise
  • Reported EPS: $-0.25
  • Estimate: $-0.16
  • Whisper: —
  • Surprise %: -56.2%
Feb 28, 2024
Dec 31, 2023 (Pre market)
0.49 Surprise
  • Reported EPS: $0.35
  • Estimate: $-0.14
  • Whisper: —
  • Surprise %: 350.0%
Oct 31, 2023
Sep 30, 2023 (Pre market)
-0.03 Surprise
  • Reported EPS: $-0.20
  • Estimate: $-0.17
  • Whisper: —
  • Surprise %: -17.6%
Jul 25, 2023
Jun 30, 2023 (Pre market)
0.38 Surprise
  • Reported EPS: $0.21
  • Estimate: $-0.17
  • Whisper: —
  • Surprise %: 223.5%
May 02, 2023
Mar 31, 2023 (Pre market)
0.03 Surprise
  • Reported EPS: $-0.18
  • Estimate: $-0.21
  • Whisper: —
  • Surprise %: 14.3%
Feb 28, 2023
Dec 31, 2022 (Pre market)
0.29 Surprise
  • Reported EPS: $0.06
  • Estimate: $-0.23
  • Whisper: —
  • Surprise %: 126.1%

Financials